Trial · NCT02117713
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) | Baseline to Week 48 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | μmol/L | MEAN |
| SECONDARY | Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA) | Baseline to week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | μmol/L | MEAN |
| SECONDARY | Change From Baseline to Week 218 in Pruritus | Baseline to Week 218 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | score on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 216 in Alanine Aminotransferase | Baseline to week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | U/L | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in Alkaline Phosphatase | Baseline to Week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | U/L | MEAN |
| SECONDARY | Change From MRX Baseline to Week 216 in Aspartate Aminotransferase | Baseline to week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | U/L | MEAN |
| SECONDARY | Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score | Baseline to week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | Points | MEAN |
| SECONDARY | Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score | Baseline to Week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | Points | MEAN |
| SECONDARY | Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase | Baseline to Week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | U/L | MEAN |
| SECONDARY | Mean Change From MRX Baseline to Week 216 in Total Bilirubin | Baseline to week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | mg/dL | MEAN |
| SECONDARY | Mean Change From MRX Baseline to Week 216 in Direct Bilirubin | Baseline to week 216 | Since most participants escalated to MRX 280 ug/kg/day, the summary is presented as a single arm. | mg/dL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02117713/outcomes